Bacteremia and vascular infections due to Gram-positive microorganisms: New therapeutic options;Bacteriemia e infecciones endovasculares por grampositivos: Nuevas opciones terapéuticas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 2, 2008, Pages 44-52

  Almirante, Benito ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antimicrobial therapy; Bacteremia; Infective endocarditis; New antibiotics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTOBIPROLE; CLOXACILLIN; DALBAVANCIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; ORITAVANCIN; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; DRUG POTENTIATION; DRUG SAFETY; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; HUMAN; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 46049120489     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13123565     Document Type: Article

References (97)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-54.
2. Esteban A, Frutos-Vivar F, Ferguson ND, Peñuelas O, Lorente JA, Gordo F, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007;35:1284-9.
3. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A, Schwartz D, et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis. 2002;34:1431-9.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17.
5. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-85.
6. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care - associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791-7.
7. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363:139-49.
8. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001;345:1318-30.
9. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012-21.
10. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis. Executive summary. Rev Esp Cardiol. 2004;57:952-62.
11. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394-434.
12. Cisneros-Herreros JM, Cobo-Reinoso J, Pujol-Rojo M, Rodríguez- Baño J, Salavert-Lletí M. Guía para el diagnóstico y tratamiento del paceinte con bacteriemia. Guías de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Enferm Infecc Microbiol Clin. 2007;25:111-30.
13. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, et al. Guidelines for the management of intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2001;22:222-42.
14. Gavaldá J, Len O, Miró JM, Muñoz P, Montejo M, Alarcón A, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med. 2007;146:574-9.
15. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Infective endocarditis due to penicillin-resistant viridans group streptococci. Clin Infect Dis. 2007;44:1585-92.
16. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006;130:947-55.
17. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-402.
18. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536-42.
19. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135-42.
20. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother. 2006;57:279-87.
21. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159-68.
22. Dobbs TE, Patel M, Waites KB, Moser SA, Stamm AM, Hoesley CJ. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol. 2006;44:3368-70.
23. Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis [serial on the Internet] [accedido Jul 2007]. Disponible en: http://www.cdc.gov/EID/content/13/7/1024.htm
24. Sánchez-Gómez JC, Fraile-Malmierca F, Valverdé- Romero ED, Sánchez M, García-Rodríguez JA, García-Sánchez JE. Linezolid-resistant Enterococcus faecalis: first report in Spain. J Chemother. 2006;18:440-2.
25. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923-9.
26. Cannon JP, Pachucki CT, Aneziokoro CO, Lentino JR. The effectiveness and safety of oral linezolid as primary or secondary treatment of bloodstream infections. A retrospective observational analysis. Infect Dis Clin Pract. 2006;14:221-6.
27. Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45:2304-8.
28. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:3002-4.
29. Jacqueline C, Navas D, Batard E, Miegeville AF, Le Mabecque V, Kergueris MF, et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:45-51.
30. Jacqueline C, Caillon J, Grossi O, Le Mabecque V, Miegeville AF, Bugnon D, et al. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:2547-9.
31. Jacqueline C, Batard E, Perez L, Boutoille D, Hamel A, Caillon J, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother. 2002;46:3706-11.
32. Del Rio A, Miró JM. ¿Podemos mejorar el pronóstico de la endocarditis estafilocócica? Enferm Infecc Microbiol Clin, Monogr. 2006;5:58-70.
33. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58:273-80.
34. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci. 2005;330:102-4.
35. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207-8.
36. Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels. Clin Infect Dis. 2003;36:675-6.
37. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50:1599-602.
38. Curtin J, Cormican M, Fleming G, Keelehan J, Colleran E. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother. 2003;47:3145-8.
39. Rodríguez-Martínez JM, Ballesta S, García I, Conejo MC, Pascual A. Actividad y permeabilidad de linezolid y vancomicina en biocapas de Staphylococcus epidermidis. Enferm Infecc Microbiol Clin. 2007;25:425-8.
40. Senneville E, Legout L, Valette M, Yazdanpanah Y, Beltrand E, Caillaux M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther. 2006;28:1155-63.
41. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents. 2007;29:233-9.
42. Soriano A, Gómez J, Gómez L, Azanza JR, Pérez R, Romero F, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis. 2007;26:353-6.
43. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994-1000.
44. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005;55:283-8.
45. Hair PI, Keam SJ, Hair PI, Keam SJ. Daptomycin : a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007;67:1483-512.
46. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis. 2003;47:539-46.
47. Thorne GM, Alder J. Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol Newsl. 2002;24:33-40.
48. Alder J, Li T, Yu D, Morton L, Silverman J, Zhang XX, et al. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob Agents Chemother. 2003;47:3561-6.
49. Smith K, Cobbs G, Dill R, Lyon D, Graves A, Avent K. Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Chemotherapy. 1990;36:428-34.
50. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
51. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007;60:7-19.
52. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007;54:567-71.
53. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1714-8.
54. Voorn GP, Kuyvenhoven J, Goessens WH, Schmal-Bauer WC, Broeders PH, Thompson J, et al. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother. 1994;38:487-93.
55. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother. 1990;34:2348-53.
56. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990;34:2081-5.
57. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother. 1989;33:1522-5.
58. Eliopoulos GM, Willey S, Reiszner E, Spitzer PG, Caputo G, Moellering RC. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986;30:532-5.
59. Snydman DR, McDermott LA, Jacobus NV. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemother. 2005;17:614-21.
60. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother. 2006;18:27-32.
61. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other betalactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:2871-5.
62. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2005;49:2735-45.
63. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:4665-72.
64. Torres-Tortosa M, Caballero-Granado FJ, Canueto J. Therapy for methicillin-resistant Staphylococcus aureus. N Engl J Med. 2006;355:2153-4.
65. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother. 2006;58:1208-14.
66. Caron F, Kitzis MD, Gutmann L, Cremieux AC, Maziere B, Vallois JM, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother. 1992;36:2611-6.
67. Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother. 1992;36:1864-9.
68. Hindes RG, Willey SH, Eliopoulos GM, Rice LB, Eliopoulos CT, Murray BE, et al. Treatment of experimental endocarditis caused by a beta-lactamase- producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1989;33:1019-22.
69. Bush LM, Boscia JA, Kaye D. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1988;32:877-81.
70. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother. 2004;53:530-2.
71. Rand KH, Houck HJ, Silverman JA. Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 2007;59:1017-20.
72. Edmiston CE, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR, et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg. 2006;192:344-54.
73. Fernández-Hidalgo N, Almirante B, Calleja R, Ruiz I, Planes AM, Rodríguez D, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother. 2006;57:1172-80.
74. Fortún J, Grill F, Martín-Dávila P, Blázquez J, Tato M, Sánchez-Corral J, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother. 2006;58:816-21.
75. Laplante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 2007 [Epub ahead of print].
76. Vaudaux P, Francois P, Bisognano C, Li D, Lew DP, Schrenzel J. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother. 2003;52:89-95.
77. Cunha BA, Hamid N, Kessler H, Parchuri S. Daptomycin cure after cefazolin treatment failure of methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung. 2005;34:442-7.
78. Weis F, Beiras-Fernández A, Kaczmarek I, Sodian R, Vicol C, Reichart B, et al. Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient. Ann Thorac Surg. 2007;84:269-70.
79. Sader HS, Jones RN. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin Infect Dis. 2006;43:798-9.
80. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285-7.
81. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006;44:655-6.
82. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol. 2006;44:595-7.
83. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058-60.
84. Mariani PG, Sader HS, Jones RN. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother. 2006;58:481-3.
85. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079-82.
86. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother. 2007;60:334-40.
87. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43:518-24.
88. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41 Suppl 5:S333-40.
89. Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol. 2006;6:486-90.
90. Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother. 2000;44:3022-7.
91. Lin SW, Carver PL, DePestel DD. Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother. 2006;40:449-60.
92. Raad I, Darouiche R, Vázquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374-80.
93. Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:3163-5.
94. Miró JM, García-de-la-Maria C, Armero Y, De-Lazzari E, Soy D, Moreno A, et al. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2007 [Epub ahead of print].
95. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998;42:981-3.
96. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005;49:4210-9.
97. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:884-8.